After a 60% Slide, One Fund Cuts Exposure to This Healthcare Tech Stock by $12.5 Million

Chicago Capital reduced its stake in PROCEPT BioRobotics (NASDAQ:PRCT) by selling 377,850 shares in Q4 — an estimated $12.53 million trade — leaving 1,190,995 shares valued at $37.47 million as of Dec. 31 and trimming the position to 0.93% of 13F assets (from 1.38%). PROCEPT, which has a $1.65 billion market cap and a price of $29.61 on Jan. 26 (down 60.4% Y/Y), reported strong top-line growth (Q3 revenue $83.3M, +43% YoY; TTM revenue $299.91M) but remains unprofitable (TTM net loss $84.58M; adjusted EBITDA loss $7.4M last quarter) while guiding 2026 revenue to $410–$430M. The trade appears to be position-sizing/risk management by a fund concentrated in large-cap tech names rather than a clear repudiation of PROCEPT’s growth trajectory.

Analysis

Market structure: Chicago Capital’s trim of PRCT signals institutional risk‑management, not necessarily thesis abandonment; short‑term sellers benefit (liquidity takers, options sellers) while retail and concentrated small‑cap medtech holders are hurt. PRCT’s installed‑base model (653 U.S. systems) creates recurring consumables demand, so winners longer‑term are consumable‑leverage players if adoption continues; losers are single‑product names that can’t scale consumables fast enough.

Risk assessment: Tail risks include an adverse FDA guidance/relabeling, reimbursement cuts by CMS, or a capital‑markets funding shock forcing dilutive raises — any of which could halve equity value in 3–12 months. Immediate (days) impact = volatility spike and widened IV; short term (1–3 months) = guidance/quarterly cadence; long term (12–24 months) depends on installed‑base scaling to ~1,000+ systems to justify current valuation. Hidden dependency: procedure adoption hinges on hospital capital cycles and urologist training, creating a 6–12 month lag between sales and consumable revenue.

Trade implications: For stock traders, asymmetric opportunity exists but execution risk is high. Use small, defined‑risk positions: conditional buys at < $28 with stops, or defined option spreads to capture mean reversion if guidance is met; rotate trimmed capital into mega‑cap tech (GOOGL/NVDA) for lower execution risk. Catalyst watchlist: quarterly installs, 2026 revenue cadence versus guidance ($410–430M), and any CMS policy moves in the next 90 days.

Contrarian angle: Consensus may overprice permanent demand failure; historical parallel = Intuitive Surgical’s early loss→consumable cash‑cow path. If PRCT sustains >25–30% revenue growth and keeps gross margin ≥60% for two consecutive quarters, upside >50% is plausible within 12–18 months. Conversely, failure to show margin improvement or a single large reimbursement reversal is a binary downside trigger.

Key Decisions for Investors

• Establish a tactical long position in PRCT (1–2% of portfolio) only if price ≤ $28; set hard stop-loss at $22 (≈20–25% below entry) and a 12–18 month target of $45 (≈60% upside) contingent on management hitting 2026 guidance ($410–430M) and sequential install growth of ≥15% QoQ.
• If owning PRCT, buy 3‑month ATM protective puts (or put‑spread to cap cost) to limit downside to ~20–30% ahead of the next quarterly install/revenue print; size hedges to cover 75–100% of the position not to exceed 0.5% of portfolio cost.
• Reduce PRCT exposure to <0.5% of AUM if management misses next two monthly/quarterly install targets; redeploy proceeds into mega‑cap tech: add GOOGL or NVDA to reach a combined 6–8% AUM (favor NVDA if AI hardware demand persists), holding 6–12 months.
• Use a conditional add rule: add to PRCT (incremental 0.5–1%) within 3 months only if (a) U.S. installed base ≥800 systems or (b) adjusted EBITDA loss narrows by ≥50% YoY; if neither occurs, consider selling remaining position.